You should consider shares of TransUnion (NYSE:TRU) and Aquestive Therapeutics Inc. (NASDAQ:AQST) if you are looking for a great stocks to invest in. Starting with the TRU shares, which traded at $84.77 at the close of the recent session, dropping -1.28%. On Tuesday, the company’s shares shed -$1.1 from its value which represented in intraday trading. The stock is now 31.28% higher in year-to-date (YTD) trading. TRU’s intraday high was $85.20 while its lowest price touched $84.31. The stock’s 52-week high price is $87.39, which means the current price is at -3.00%. In terms of trading activity, the daily trading volume fell to 1040815 against 200-day average trading volume of 1,177,427 shares.
What are analyst forecasts for TransUnion (NYSE:TRU)?
At a consensus rating of 4.23, TRU is trending as a streaking Moderate Buy, as it has been the case a month ago when 12 analysts called it a Moderate Buy. Two months ago, 12 analysts recommended, on average, that TRU stock is a Moderate Buy. The Services company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $85.07 on the day.
Forecasts for TransUnion (NYSE:TRU) give the stock a fair value for the growth of 5.81% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $90.00, which means the price per share could rise by nearly $5.23. The price range target is between a low of $74.00 and a high of $100.00. The stock would need to gain by about $15.23 to hit the estimated high or 0.62% from its 12-month low.
The consensus among 17 analysts is that it is a good time for one to Overweight in the TransUnion. 9 analysts rate TRU as a Buy, with 0 of 17 analysts rate it as a Sell. 1 have valued the stock as Overweight and 6 have recommended that investors Hold.
TransUnion (NYSE:TRU) Upgrades and Downgrades
In terms of rating changes, Jefferies on November 22, 2019, Initiated TransUnion (TRU) at Hold. Analysts at Atlantic Equities have assigned a Neutral rating for the stock in their research note on July 30, 2019. Moreover, Exane BNP Paribas analysts issued a rating of Neutral for the stock on March 15, 2019, giving it a price target of $66 for the next 12 months. On December 07, 2018, the stock earned a Neutral rating due to an analyst call from Credit Suisse, while analysts from Atlantic Equities on October 24, 2018 suggested that the stock is Overweight.
Aquestive Therapeutics Inc. (NASDAQ:AQST) adds $0.01 on Tuesday
The AQST stock has risen 38.89% year-to-date and is currently trading at $8.75, which is -12.50% below its 52-week high. The company shares gained 0.11% on the day and have risen nearly 196.61% off a low hit. At current levels, Aquestive Therapeutics Inc. has a valuation of about $53.00M. As of 12/03/19, this stock has risen 16.05% during the week and closed at $8.74 in the previous session. However, recent Aquestive Therapeutics Inc. stock performance shows that AQST shares are 113.94% up over the last month, and 135.22% up for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.51, with the trailing 12-month share earnings at -$2.71. The ratio is expected to be up by 7.40% for the current year 2019 and 23.00% for next year. But will the AQST stock surprise in the current quarter results, where the -$0.74 actual EPS reported on 9/29/2019 surprised by -7.20% or was lower by -$0.05 from the estimated -$0.69.
Sales Growth to climb 22.60% for the year
How well will Aquestive Therapeutics Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $9.7M and $11.2M in current quarter sales. The consensus estimated for the current quarter is $10.19M from sales. Forecasts for this fiscal year are between $45.9M and $47.4M and the consensus estimate for sales is at $46.36M. AQST has its next quarter sales estimates at between $8.9M and $12.1M, with the quarter-over-quarter growth estimates at -16.40% and the annual growth forecast for the year at 22.60%.
Who owns shares in Aquestive Therapeutics Inc. (AQST)?
Let’s briefly focus on the share ownership of the Aquestive Therapeutics Inc. (NASDAQ:AQST) stock, where we find that 66.50% of shares are held by institutions. Bratton Capital Management, LP tops the list of institutional owners as it is holding 11.5 million shares or 45.93% of shares outstanding. Perceptive Advisors Llc and Blackrock Inc. held 2.11 million and 370718.0 representing 8.44% and 1.48% respectively at the close of the last trading session. As of Sep 29, 2019, Massachusetts Financial Services Co. accounted for 293625.0 shares at over 933727.0. This represented 1.17% of shares outstanding. Vanguard Group, Inc. (The) held 279412.0 shares at over 888530.0 representing 1.12% of shares outstanding.
AQST Insider Activity
On 2/28/2019, by the name Schobel A Mark sold 6721.0 shares worth $54100.0 at the price of $8.05 per share. Filings also show that Maxwell John T bought a total of 5000.0 shares on 12/06/2018 valued at $44400.0. Since the last insider activity, the company’s share price has dropped -0.11%.